Locally advanced head and neck cancers: Recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy;Cancers des voies aérodigestives supérieures (VADS) localement avancés: Recommandations d'un panel d'experts et de perspectives pour l'utilisation du schéma TPF (docétaxel, cisplatine, 5-fluoro-uracile) en induction

Bulletin du Cancer

Volumn 96, Issue 10, 2009, Pages 1013-1028

  Bardet, E ^a   Bourhis, J ^b   Cals, L ^c   Fayette, J ^d   Guigay, J ^b   Hans, S ^e   Lacau Saint Guily, J ^f   Lagarde, F ^g   Lallemant, B ^h   Milano, G ⁱ   Rolland, F ^a   Lefebvre, J L ^j  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Centre Hospitalier Intercommunal   (France)

^d CENTRE LÉON BÉRARD   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f HÔPITAL TENON   (France)

^g Centre Hospitalier Régional   (France)

^h DEPARTMENT OF NEUROLOGY   (France)

ⁱ CENTRE ANTOINE LACASSAGNE   (France)

^j CENTRE OSCAR LAMBRET   (France)

more..

Author keywords

Docetaxel; Head and neck cancers; Indications; Predictive factors; Treatment modalities

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; TAXOID; TPF PROTOCOL;

ADVANCED CANCER; ANEMIA; ANOREXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DYSPHAGIA; DYSPHONIA; ESOPHAGITIS; FEBRILE NEUTROPENIA; HEAD AND NECK CARCINOMA; HUMAN; INFECTION; MEDICAL SPECIALIST; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; REVIEW; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; CONFERENCE PAPER; CONSENSUS; CONSENSUS DEVELOPMENT; FEMALE; FRANCE; HEAD AND NECK TUMOR; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REMISSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; CONSENSUS; FEMALE; FLUOROURACIL; FRANCE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TAXOIDS;

EID: 70350514517     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0951     Document Type: Review

References (50)

1. Hill C, Doyon F. The frequency of cancer in France: mortality trends since 1950 and summary of the report on the causes of cancer. Bull Cancer 2008 ; 95 : 5-10.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007 ; 57 : 43-66.
3. Monnerat C, Faivre S, Temam S, Bourhis J, Raymond E. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 2002 ; 13 : 995-1006. (Pubitemid 34884999)
4. Posner MR, Haddad RI, Wirth L, Norris CM, Goguen LA, Mahadevan A, et al. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol 2004 ; 31 : 778-785 (Pubitemid 39602683)
5. Decker DA, Drelichman A, Jacobs J, Hoschner J, Kinzie J, Loh JJ, et al. Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluoro-uracil in stage III and IV squamous cell carcinoma of the head and neck. Cancer 1983 ; 51 : 1353-1355 (Pubitemid 13162126)
6. Ensley JF, Jacobs JR, Weaver A, Kinzie J, Crissman J, Kish JA, et al. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 1984 ; 54 : 811-814 (Pubitemid 14058432)
7. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991 ; 324 : 1685-1690
8. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996 ; 88 : 890-899 (Pubitemid 26230640)
9. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994 ; 86 : 265-272 (Pubitemid 24057404)
10. Domenge C, Hill C, Lefebvre JL, De Raucourt D, Rhein B, Wibault P, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'étude des tumeurs de la tête et du cou (GETTEC). Br J Cancer 2000 ; 83 : 1594-1598
11. Zorat PL, Paccagnella A, Cavaniglia G, Loreggian L, Gava A, Mione CA, et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 2004 ; 96 : 1714-1717 (Pubitemid 39591589)
12. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000 ; 355 : 949-955
13. Posner M, Glisson B, Frenette G, Al-Sarraf M, Colevas AD, Norris CM, et al. Multicenter phase I-II trial of docetaxel, cisplatin and fluoro-uracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001 ; 19 : 1096-1104 (Pubitemid 32176286)
14. Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan C, et al. Docetaxel, cisplatin and 5-fluoro-uracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer 2003 ; 97 : 412-418 (Pubitemid 36133808)
15. Schrijvers D, Van Herpen C, Kerger J, Joosens E, Van Laer C, Awada A, et al. Docetaxel, cisplatin and 5-fluoro-uracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann Oncol 2004 ; 15 : 638-645 (Pubitemid 38559602)
16. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluoro-uracil and docetaxel in unresectable head and neck cancer. N Engl J Med 2007 ; 357 : 1695-1704 (Pubitemid 350005151)
17. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluoro-uracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007 ; 357 : 1705-1715 (Pubitemid 350005152)
18. Calais G, Pointreau Y, Alfonsi M, Sire C, Tuchais C, Tortochaux J, et al. Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluoro-uracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-2001. J Clin Oncol, ASCO Annual Meeting Proceedings Part I 2006; 24 (suppl.18) : 5506 (abstract).
19. Paccagnella A, Buffoli A, Koussis H, Gava A, Franceschi T, Gardani G, et al. Concomitant chemoradiotherapy (CT/RT) vs neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluoro-uracil (TPF) followed by CT/RT in locally advanced head and neck cancer. Final results of a phase II randomized study. J Clin Oncol, ASCO Annual Meeting Proceedings Part I 2008; 26 (suppl) : 6000 (abstract).
20. Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ, Ang KK, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 2006 ; 24 : 3693-3704 (Pubitemid 46630546)
21. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006 ; 24 : 3187-3205 (Pubitemid 46638957)
22. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006 ; 42 : 2433-2453 (Pubitemid 44442936)
23. Standards, options et recommandations pour l'utilisation des antiémétiques en cancérologie. www.fnclcc.fr. 1998 : 13-48.
24. e édition). 2010, XXII : 1-2.
25. Scotté F, Tourani JM, Banu E, Peyromaure M, Levy E, Marsan S, et al. Multicenter study of a frozen glove to prevent docetaxelinduced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 2005 ; 23 : 4424-4429 (Pubitemid 46207017)
26. Garabige V, Giraud P, De Rycke Y, Girod A, Jouffroy T, Jaulerry C, et al. Impact of nutrition management in patients with head and neck cancers treated with irradiation: is the nutritional intervention useful? Cancer Radiother 2007 ; 11 : 111-116 [Article in French].
27. Lee W, Lockhart AC, Kim RB, Rothenberg ML. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 2005 ; 10 : 104-111 (Pubitemid 40261949)
28. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006 ; 439 : 353-357 (Pubitemid 43128862)
29. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005 ; 23 : 1169-1177 (Pubitemid 46202273)
30. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003 ; 362 : 362-369 (Pubitemid 36957839)
31. Febbo PG, Thorner A, Rubin MA, Loda M, Kantoff PW, Oh WK, et al. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res 2006 ; 12 : 152-158 (Pubitemid 43166189)
32. Johnston PG, Mick R, Recant W, Behan KA, Dolan ME, Ratain MJ, et al. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 1997 ; 89 : 308-313 (Pubitemid 27085893)
33. Kawasaki G, Yoshitomi I, Yanamoto S, Mizuno A. Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002 ; 94 : 717-723 (Pubitemid 41124708)
34. Kawano K, Goto H, Kanda T, Yanagisawa S. Predictive value of immunohistochemical thymidylate synthase expression for histological response to Tegafur/Uracil (UFT) in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2003 ; 32 : 633-637 (Pubitemid 37461506)
35. Etienne MC, Chéradame S, Fischel JL, Formento P, Dassonville O, Renée N, et al. Response to fluoro-uracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995 ; 13 : 1663-1670
36. Chéradame S, Etienne MC, Formento P, Schneider M, Dassonville O, Demard F, et al. Tumoral-reduced folates and clinical resistance to fluoro-uracil-based treatment in head and neck cancer patients. J Clin Oncol 1997 ; 15 : 2604-2610 (Pubitemid 27289891)
37. Lévi F, Metzger G, Massari C, Milano G. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 2000 ; 38 : 1-21.
38. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002 ; 94 : 936-942 (Pubitemid 34778092)
39. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998 ; 19 : 275-280
40. Park DJ, Stoehlmacher J, Lenz HJ. Tailoring chemotherapy in advanced colorectal cancer. Curr Opin Pharmacol 2003 ; 3 : 378-385 (Pubitemid 36908941)
41. Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 2004 ; 14 : 959-970
42. Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-Saint-Guily J, Soria JC, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007 ; 13 : 3855-3859 (Pubitemid 47037591)
43. Baker S, Verweij J, Cusatis G, van Schaik R, Marsh S, Orwick S, et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 2008. doi:10.1038/clpt.2008.95.
44. Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 2006 ; 12 : 5786-5793 (Pubitemid 44629610)
45. Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 2008 ; 99 : 967-972 (Pubitemid 351997599)
46. Chang JC, Makris A, Gutierrez MC, Hilsenbeck SG, Hackett JR, Jeong J, et al. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat 2008 ; 108 : 233-240 (Pubitemid 351311356)
47. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2008. doi:10.1007/s10549-008-0128-9.
48. Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GK, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007 ; 13 : 7413-7420
49. Rody A, Karn T, Gätje R, Ahr A, Solbach C, Kourtis K, et al. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubuleassociated protein tau, is highly predictive of tumor response. Breast 2007 ; 16 : 86-93. (Pubitemid 46172862)
50. Remaud G, Boisdron-Celle M, Hameline C, Morel A, Gamelin E. An accurate dihydro-uracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice. J Chromatogr B Analyt Technol Biomed Life Sci 2005 ; 823 : 98-107. (Pubitemid 41116751)